3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Ovarian Neoplasms
4
Fallopian Tube Neoplasms
4
Endometrial Neoplasms
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Urinary Bladder Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Leiomyosarcoma
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Prostate Cancer Metastatic
1
Mesothelioma, Malignant
1
Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Endometrioid
1
Interventions
Oxaliplatin
5
Capecitabine
5
Paclitaxel
4
apatinib
3
Fluorouracil
3
Docetaxel
3
Cisplatin
3
S 1 (combination)
2
Leucovorin
2
titanium silicide
1
rucaparib
1
relatlimab
1
raltitrexed
1
pazopanib
1
olaparib
1
linrodostat
1
endostar protein
1
durvalumab
1
dacomitinib
1
capivasertib
1
camrelizumab
1
Sunitinib
1
SHR-1701
1
Nivolumab
1
Ipilimumab
1
HMPL-013
1
Epirubicin
1
Doxorubicin
1
CF regimen
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Advanced Gastric Cancer
×
rucaparib
×
Clear all
NCT02935634
2023-06-09
FRACTION-GC
Bristol-Myers Squibb
Phase 2
Completed
190 enrolled
25 charts